[Articles] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

[Articles] Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

The Lancet Neurology

Increased clinical disease activity associated with atacicept suggests that the role of B cells and humoral immunity in multiple sclerosis is complex. For studies that explore therapeutic immunomodulation in multiple sclerosis, rigorous monitoring for negative effects on clinical and MRI outcomes is warranted.

Original Article: http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70028-6/abstract?rss=yes

Julio Pereira 
www.neurocirurgiabr.com
http://www.linkedin.com/in/juliommais
http://lattes.cnpq.br/7687651239699170
Consultório (11) 3141-9550 / 3141-9553